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AbstrACt 
Objective Evaluate relative clinical effectiveness of 
treatment options for type 2 diabetes mellitus (T2DM) 
using a statistical model of real-world evidence within 
UK general practitioner practices (GPP), to quantify the 
opportunities for diabetes care performance improvement.
Method From the National Diabetes Audit in 2015–2016 
and 2016–2017, GPP target glycaemic control (TGC—
%HbA1c ≤58 mmol/mol) and higher glycaemic risk 
(HGR —%HbA1c results >86 mmol/mol) outcomes were 
linked using multivariate linear regression to prescribing, 
demographics and practice service indicators. This was 
carried out both cross-sectionally (XS) (within year) 
and longitudinally (Lo) (across years) on 35 indicators. 
Standardised β coefficients were used to show relative 
level of impact of each factor. Improvement opportunity 
was calculated as impact on TGC & HGR numbers.
results Values from 6525 GPP with 2.7 million T2DM 
individuals were included. The cross-sectional model 
accounted for up to 28% TGC variance and 35% HGR 
variance, and the longitudinal model accounted for up 
to 9% TGC and 17% HGR variance. Practice service 
indicators including % achieving routine checks/blood 
pressure/cholesterol control targets were positively 
correlated, while demographic indicators including 
% younger age/social deprivation/white ethnicity 
were negatively correlated. The β values for selected 
molecules are shown as (increased TGC; decreased HGR), 
canagliflozin (XS 0.07;0.145/Lo 0.04;0.07), metformin (XS 
0.12;0.04/Lo –;–), sitagliptin (XS 0.06;0.02/Lo 0.10;0.06), 
empagliflozin (XS–;0.07/Lo 0.09;0.07), dapagliflozin (XS 
–;0.04/Lo –;0.4), sulphonylurea (XS −0.18;−0.12/Lo–;–) 
and insulin (XS−0.14;0.02/ Lo−0.09;–). Moving all GPP 
prescribing and interventions to the equivalent of the top 
performing decile of GPP could result in total patients in 
TGC increasing from 1.90 million to 2.14 million, and total 
HGR falling from 191 000 to 123 000.
Conclusions GPP using more legacy therapies such as 
sulphonylurea/insulin demonstrate poorer outcomes, while 
those applying holistic patient management/use of newer 
molecules demonstrate improved glycaemic outcomes. If 
all GPP moved service levels/prescribing to those of the 
top decile, both TGC/HGR could be substantially improved.
IntrOduCtIOn
The National Diabetes Audit (NDA) of England1 
reported that over the period 2006/2007 
to 2016/2017, the diagnosed population of 
people with type 2 diabetes mellitus (T2DM) 
in England rose by 22% from 2.3 million to 
2.8 million and the proportion of people with 
T2DM achieving target glycaemic control 
(TGC) with glycosylated haemoglobin 
(HbA1c) ≤7.5% (58 mmol/mol) fell from 
strengths and limitations of this study
 ► This study provides insights into the inter-relation-
ship between the portfolio of type 2 diabetes mel-
litus (T2DM) medicines and service interventions 
in primary care and patient outcomes in real-world 
settings not addressed by randomised control trial 
approaches.
 ► The databases used in this study, including the 
National Diabetes Audit and primary care prescrib-
ing database, offer a comprehensive summary of 
participating practice activities in the care of T2DM 
within primary care.
 ► Multivariate regression analysis is an established 
methodology in identifying associations between a 
selected range of variables and outcomes in actual 
clinical practice.
 ► One limitation is that association cannot be assumed 
to being causal, with potential confounding factors 
such as comorbidities and other local behavioural 
factors being contributors to the results.
 ► Restricted use of certain factors such as new medi-
cations being introduced may have limited the ability 
of this model to identify their significance.
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66.5% to 65.7%. In the same period, those patients at 
higher glycaemic risk (HGR) with HbA1c >10.0% (86 
mmol/mol) decreased from 7.0% to 6.7%.
A recent report, Prescribing for Diabetes England 2006–
2007 to 2016/2017,2 describes a 70% increase in total 
expenditure on drugs used to treat T2DM over that 
period from £160 to £272 million/year respectively, 
with the main cost drivers being newer agents such as 
glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl 
peptidase-4 (DPP-4) inhibitors and sodium–glucose 
cotransporter-2 (SGLT-2) inhibitors.
With growing pressures on local primary care services, 
optimising how general practitioner practices (GPP) 
deliver care to T2DM patients is critical. For optimisation 
of care to take place, and resources to be targeted at the 
right interventions, a best practice benchmark is required 
defining the factors more likely to provide improved 
outcomes. We recently reported that some classes of 
diabetes therapies such as SGLT-2 inhibitors and GLP-1 
analogues are associated with a larger proportion of indi-
viduals achieving HbA1c <58 mmol/mol.3 That paper 
reported that in year-on-year analysis, SGLT-2 inhibitor 
prescribing was associated with a greater reduction in 
patients at HGR than occurred with GLP-1 analogues. 
Targeting the more effective agents is therefore funda-
mental to longer term affordability.
This subsequent paper seeks to determine at GPP level 
the differences in the relation of individual medicines and 
service interventions to outcomes, by determining factor 
correlation with the proportion of T2DM patients who are 
well controlled (%HbA1c Last Result ≤58 mmol/mol), 
and those who have poor glycaemic control (%HbA1c 
Last Result >86 mmol/mol). The objective is to identify 
a ‘performance profile’ of factors positively correlated 
with T2DM patient outcomes which can provide a bench-
mark against which GPP can compare and improve 
their management of, and prescribing for, T2DM. This 
profile of factors can also support a more informed 
debate around the prioritisation criteria for investment 
in existing and future T2DM therapies and interventions 
that can deliver greater relative benefits.
MethOds
This latest analysis is based on current publicly available 
diabetes NHS data sets including the NDA,1 Quality 
and Outcome Framework (QoF)4 and National Primary 
Care Prescribing database5 together with Public Health 
Observatory data.6 A consolidated data set was created 
and extracted using MS Excel 64 bit Power Pivot and 
extracted data were analysed using the Analyse-it add in 
- the same multivariate regression methodology as previ-
ously published papers. This analysis linked medicines 
and other therapeutic interventions at English GPP level 
with glycaemic control outcomes as defined by relative 
proportions of patients falling within the given HbA1c 
control categories as reported in the NDA.
Multivariate regression analysis is a statistical proce-
dure for analysis of data involving more than one type of 
measurement or observation. The approach uses simul-
taneous analysis of variables to determine the level of 
relation between factors, using p-values and standardised 
β-values, the latter referring to a standardised regression 
coefficient that compares the strength of the effect of 
each individual independent variable to the dependent 
variable. This method can identify real-world correlations 
of one variable with another variable—in this case T2DM 
interventions with disease control. Longitudinal studies 
may give more precise estimates of temporal changes or 
treatment effects than cross-sectional studies of the same 
size. When risk factors vary more across space at a fixed 
moment in time than at a fixed location across time, 
cross-sectional studies will tend to give more precise esti-
mates of risk factor effects. Hence, both cross-sectional 
and longitudinal approaches were used.
A range of medicine and non-medicine intervention 
factors were identified related to type 1 and type 2 diabetes 
from NDA and QoF data sets. The medicine classes and 





 ► SGLT-2 inhibitors (dapagliflozin, empagliflozin, 
canagliflozin).
 ► DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, 
sitagliptin, vildagliptin).
 ► GLP-1 agonists (dulaglutide, exenatide (2/
day+weekly), liraglutide, lixisenatide).
For medicines, all data were adjusted for ‘per patient' 
using 'defined daily dose’ (or ‘DDD’7 ,which is the average 
daily dose of a particular medicine as defined by the 
WHO). The approach allowed overall patients presribed 
to be calculated, but could not show individual patient 
prescribing profiles either in combination (except where 
the British National Formulary (BNF) code itself referred 
to a combined therapy) or the actual doses being applied. 
The % of people with type 2 on insulin was estimated by 
subtracting the amount of insulin for type 1 (estimated by 
multiplying the recorded number of type 1 in the practice 
register by 50 units/day and 365) from the total and then 
dividing the remainder by 100 units/day and 365. This 
figure was then taken as % of the type 2 recorded register. 
Other non-medicine service factors were also included 
in the analysis to determine the level to which these 
would predict outcomes. These included NDA metrics 
such as blood pressure, cholesterol levels, renal func-
tion (creatinine and urine albumin/creatinine ratio), 
foot checks, body mass index and smoking. Non-HbA1c 
outcomes were also included in the analysis including % 
patients with blood pressure ≤140/80 and % patients with 
total serum cholesterol <4 mmol/L.
Impact on outcomes was defined by two measures:
 ► % of patients within GPPs at TGC (HbA1c ≤58 mmol/
mol) and
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 ► % of patients within GPPs at HGR (HbA1c >86 mmol/
mol).
While 35 different factors (see online supplemen-
tary appendix) were originally tested, only 20 of those 
achieved correlation p-values below 0.05, and were 
subsequently included in the results. In relation to drug 
combinations, metformin plus other oral agents are 
included in the analysis although these preparations 
are little used in comparison with individual prescribed 
molecules.8 Therefore, their contribution to the overall 
regression analysis is likely to be minimal. In relation to 
double (eg, metformin+gliclazide), triple (eg, metform-
in+SGLT2+GLP-1 analogue) and quadruple therapy, the 
contributions of each agent are accounted for separately 
in the analysis.
As a real-world analysis, resultant correlations could 
be influenced by confounding factors. Including poten-
tial confounders in the regression may decrease the bias 
of the treatment effect; however, adding more variables 
can decrease statistical power in small samples because 
it increases the variance (spread) around the regression 
estimate by decreasing the degrees of freedom (df).9 
The model was designed to reduce the potential effect 
of these by conducting analysis on consolidated popu-
lations of over 100 people within each GPP practice. In 
addition, the wide range of variables of different classes 
taken from different sources over different time periods 
meant potential unidentified confounders were more 
likely to be accounted for in one or more of the iden-
tified measured variables, reducing likely confounding 
in the regression analysis. Applying both longitudinal 
and cross-sectional models to evaluate the same data sets 
is also more likely to reduce unaccounted influencing 
factors. However, despite approaches to reduce these 
confounders, the possibility of unidentified influences on 
correlation results remains.
Another challenge with diabetes is the long-term nature 
of the disease. Outcomes status can be influenced by a 
number of historical factors such as choice of medicine 
and quality of interventions such as reviews. This means, 
for example, that patients currently prescribed insulin 
could be due to previous poor choice of oral medicines 
at an earlier point in the patient’s disease cycle, rather 
than an intrinsic aspect of their disease. Therefore, two 
approaches were applied in the regression analysis:
 ► Cross-sectional: This explored the association of patient 
outcomes with different levels of prescribing and 
other factors across different GPPs for the latest year 
of data where regression analysis was applied to the 
cohort of GPP in 2016–2017. This mode of analysis is 
more sensitive to differences in prescribing between 
GPP.
 ► Longitudinal: This explored the association of patient 
outcomes with different levels of prescribing and 
other factors within the same GPP across 2 years of 
data, regression analysis being applied between the 
net change in outcome levels and the change in factor 
level between 2015–2016 and 2016–2017. This mode 
of analysis is more sensitive to newer agents for which 
there is significant change in year-on-year prescribing 
or agents whose use is declining year-on-year.
Two different metrics were calculated for both TGC 
and HGR in both cross-sectional and longitudinal views.
 ► Standardised beta coefficient: For all indicators with p 
value <0.05, the standardised beta coefficient was 
calculated to show the direction and level of associ-
ation of change in that indicator against the chosen 
outcome. The sign was adjusted so that a positive value 
was associated with positive change in that outcome 
that is, increase in TGC and reduction in HGR.
 ► Potential outcome numbers affected by a change in indicator 
value: As GPP demographics cannot be changed, they 
were not included in the analysis. As all indicators 
can be presented as a ratio to the total T2DM popu-
lation, applying the calculated regression coefficient 
to a difference between indicator values and multi-
plying that by the total national T2DM population 
would give an estimate of the change in numbers of 
patients moving into TGC or out of HGR if GPP were 
to achieve the same pattern of clinical behaviours as 
those GPP in the top performance decile for patient 
outcomes. This assumes that the observed positive 
or negative association had some causal impact, 
accepting that confounders cannot be ruled out in a 
study of this nature.
For the cross-sectional analysis, the regression coeffi-
cient was applied to the difference between the median 
population value and the 10th and 90th percentile values 
(as indicated by the sign) of all the GPP being evaluated 
for that indicator, providing a best practice correlation 
standard.
For the longitudinal analysis, the regression coefficient 
was applied to the difference in indicator value to the 
previous year, multiplied against the total T2DM popu-
lation to provide an indication of the association of the 
annual change of that indicator with change in outcomes.
As the indicators are associated with a total number of 
patients, the number of patients required to achieve a unit 
change in the outcome from that indicator can be calcu-
lated. This figure, the number needed to treat (NNT), 
can be obtained through an inversion of the regression 
coefficient for that indicator.
Patient involvement
No patients, carers or lay people were involved in the 




Cross-sectional data from 2016 to 2017 operational year 
were analysed which included 6614 GPP (table 1) who had 
participated in the NDA, each with more than 100 T2DM 
patients per practice. These results were based on a total 
registered population for England of 57.9 million. The 
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Figure 1 Cross-sectional—standardised beta value (β). BP, blood pressure; DPP-4, dipeptidyl peptidase-4 inhibitor; GLP-1, 
glucagon-like peptide-1 agonist; HGR, higher glycaemic risk; SGLT-2, sodium–glucose cotransporter-2 inhibitor; TGC, target 
glycaemic control. 
Table 1 Participation in the study
GPP participation in 2016–2017 QoF NDA
NDA >100 T2DM 
patients
GPP also participating in 2015–
2016
Number of practices 7366 6873 6614 5488
Population 57 925 672 54 953 783 53 837 296 45 588 943
DM register 3 112 478 2 958 290 2 927 864 2 471 551
NDA T2 2 699 945 2 683 420 2 267 835
NDA T2 HbA1c % ≤58 66.9% 66.9% 66.8%
NDA T2 HbA1c % >86 6.7% 6.7% 6.7%
GPP, general practitioner practice; NDA, National Diabetes Audit; QoF, Quality and Outcome Framework.
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multiple regression model results (figure 1) accounted 
for 29% of the variance in TGC and 35% of the variance 
in HGR groups.
Use of specific medication showing positive association 
to both TGC control (ie, increasing numbers in this group) 
and HGR (decreasing numbers in this group) included 
metformin (single and combination prescribing) (TGC 
β=0.119; p<0.001; HGR β=0.04; p<0.001), canagliflozin 
(TGC β=0.07; p<0.001; HGR β=0.09; p<0.001) and sita-
gliptin (TGC β=0.06; p<0.001; HGR β=0.02; p<0.03). 
Medicines only showing positive correlation with HGR 
reduced numbers included dapagliflozin (HGR β=0.04; 
p<0.001) and empagliflozin (HGR β=0.03; p<0.01). Use of 
sulphonylurea (TGC β=−0.185; p<0.001; HGR β=−0.123; 
p<0.001) and insulin (TGC β=−0.14; p<0.001; HGR 
β=−0.02; p<0.001) was negatively associated, correlating 
with decreased numbers at TGC and increased numbers 
of HGR.
Demographic factors also demonstrated negative 
impact on both outcomes, including GPP with higher 
% of younger age patients (TGC β=−0.28; p<0.001; HGR 
β=−0.36; p<0.001) and greater social deprivation (TGC 
β=−0.07; p<0.001; HGR β=−0.21; p<0.001).
Non-medicine local service activities that showed 
positive association to both outcome groups included 
% completion of cholesterol checks (TGC β=0.15; 
p<0.001; HGR β=0.08; p<0.001), % measured cholesterol 
levels <4 mmol/mol (TGC β=0.12; p<0.001; HGR β=−0.10; 
p<0.001) and % blood pressure results ≤140/80 mm Hg 
(TGC β=0.11; p<0.001; HGR β=0.08; p<0.001).
longitudinal analysis
Longitudinal data compared results with the previous 
2015–2016 year. This covered 5488 GPP who had partic-
ipated in NDA for both years each with more than 
100 T2M patients and included results in 2016–2017 
from 2.26 million T2 patients from a total population of 
45.6 million. The model (figure 2) identified 9% of the 
variance in TGC change and 17% in HGR change.
Medicines showing positive associations with TGC and 
HGR included sitagliptin (TGC β=0.1; p<0.001; HGR 
B=0.07; p<0.001), empagliflozin (TGC β=0.09; p<0.001; 
HGR β=0.07; p<0.001) and canagliflozin (TGC β=0.04; 
p<0.001; HGR β=0.06; p<0.001).
Local service activities showing positive association to 
improved outcomes included % identification of T2DM 
on the QoF register (TGC β=0.13; p<0.001; HGR β=0.07; 
p<0.001), % completion of foot checks (TGC β=0.12; 
p<0.001; HGR β=0.37; p<0.001), % completion of blood 
pressure checks (TGC β=0.8; p<0.001) and % HbA1c 
glycaemic control being achieved in their type 1 DM popu-
lation (TGC β=0.13; p<0.001; HGR β=0.07; p<0.001).
Impact of applying cross-sectional findings to population
The potential impact of GPP across England adjusting 
prescribing and service practices to be comparable 
to those of GPP in the top decile of T2DM outcomes 
performance (figure 3) could bring an estimated 238 100 
more patients into TGC, equivalent to 15% improve-
ment. Better delivery of local service factors by ensuring 
cholesterol and blood pressure checks are comparable to 
the top 10 percentile level could bring a further 70 000 
people into TGC. For prescribing, reducing levels of 
sulphonylurea to 0.33 and use of insulin to 0.073 DDD/
T2DM population would increase TGC by 55 000, while 
increasing metformin to 0.625 and canagliflozin to 0.024, 
sitagliptin 0.138, glitazone to 0.068 DDD/T2DM popula-
tion would increase TGC by a further 44 000 patients.
Opportunity for improvement can be expressed as 
NNT for each significant factor, through increases in 
canagliflozin (3), metformin (11), sitagliptin (13) and 
decreased sulphonylurea (20). Assuming limited influ-
ence of confounding factors, aligning clinical practice 
with the top decile of GPP identified in this analysis could 
contribute to almost 70,000 people with T2DM moving 
out of the HGR category. Of this total, increasing compli-
ance with local service activities such as cholesterol and 
blood pressure control could contribute to 30,000 moving 
out of the HGR category; reducing prescribing of sulpho-
nylurea and insulin could contribute to a further 13,000 
reduction; while increasing dapagliflozin, canagliflozin, 
empagliflozin, metformin and sitagliptin could contribute 
to a further 24,500 reduction in HGR numbers. Opportu-
nity for improvement for HGR is shown as NNT through 
increases in canagliflozin (6), metformin (11), empagli-
flozin (14), dapagliflozin (20) and sitagliptin (71); and 
decrease in sulphonylurea (20).
Applying longitudinal findings to explain actual year on 
changes
From the longitudinal analysis (figure 4), there was an 
equivalent annual increase of 25,235 patients in the TGC 
group in the total T2DM population from the previous 
year, with 13,597 coming from factors not included within 
the study (‘Factors not included in study’ refers to other 
factors that are captured in the regression constant and 
therefore not explicitly identified in the analysis). Of 
note, 17,085 came from those practices that had increased 
prescribing in either empagliflozin, linagliptin, alogliptin 
or canagliflozin. However, practices that reduced levels of 
foot-checks, cholesterol control and use of glitazone were 
associated with an estimated reduction of TGC patients 
by 12,264.
Opportunity for improvement for TGC is showed as 
NNT through increases in empagliflozin (4), canagliflozin 
(5) linagliptin (7) and alogliptin (10). There was also an 
equivalent increase of 3700 in HGR in the total T2DM 
population compared with the previous year, while other 
factors not included in the study reduced numbers by 
4540. GPPs who increased prescribing of empagliflozin, 
canagliflozin, linagliptin, dapagliflozin and alogliptin 
reduced HGR by a further 7513. For some GPPs however, 
this improvement in outcomes was offset by failure to 
perform foot-checks which was associated with an overall 
HGR increase of 11,455. Foot checks represented one 
of the most positive and significant correlations with 
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improved diabetes outocmes in GPP. Opportunity for 
improvement in HGR is shown as NNT through increases 
in empagliflozin (6), canagliflozin (6), alogliptin (10), 
linagliptin (12) and dapagliflozin (12).
dIsCussIOn
Optimising the management of diabetes in primary care 
means optimising the interventions across the primary 
care diabetes pathway. This multivariate analysis demon-
strates that of the measured variables in diabetes manage-
ment, some medicines and service activities are positively 
and more significantly associated with improved diabetes 
outcomes compared with others, both in terms of 
increasing numbers of patients who are well controlled 
(TGC group) and reducing numbers of patients who are 
poorly controlled (HGR group). Broadly speaking, three 
key factor categories were important in the performance 
of primary care diabetes care: medicines, service activities 
and demographics.
Using a novel approach, we report variation between 
performance in achievement of HbA1c targets between 
thousands of GPP and separate them by centiles. Our 
assertions are based around the notion that if even 
a proportion of GPP were brought up to the perfor-
mance level of the top 10% of GPP, then large numbers 
of people with T2DM could be brought into TGC with 
Figure 2 Longitudinal—standardised beta correlation value (β).  BP, blood pressure; DPP-4, dipeptidyl peptidase-4 inhibitor; 
GLP-1, glucagon-like peptide-1 agonist; HGR, higher glycaemic risk; SGLT-2, sodium–glucose cotransporter-2 inhibitor; TGC, 
target glycaemic control. 
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significant numbers taken out of high glycaemic risk. This 
is not attempting to attribute direct causation, rather to 
propose that service organisational change and alteration 
in prescribing practice are associated with significant 
improvements in patient outcomes, and likely associated 
longer term improvement in prognosis and reduction in 
comorbidities.
Of the medicinal interventions, canagliflozin and 
metformin showed a particular positive relation in the 
cross-sectional analysis with better glycaemic outcomes, 
with the other two SGLT-2 inhibitors empagliflozin and 
dapagliflozin showing a similar relation in the longitu-
dinal analyses. This supports previous findings of supe-
rior glycaemic control with SGLT-2 inhibitor agents as 
described elsewhere using different methodologies.10 11
DPP-4 inhibitors were consistently positively correlated 
across both analysis types, although not to the extent of 
the SGLT-2 inhibitors. Sulphonylurea and higher use of 
insulin for T2DM were negatively correlated with patient 
outcomes. This has implications for the use of sulphony-
lurea as second line after metformin and supports the 
position taken by the American Diabetes Association in 
January 2017 that sulphonylurea should not be second 
line after metformin.12
Of the service activities, in general undertaking NDA 
checks (including foot checks, blood pressure and 
cholesterol control) were positively correlated with 
improved outcomes, while the demographic factors such 
as deprivation and ethnicity were negatively correlated. 
Previous studies have indicated that in the UK, popula-
tion demographics can have a profound impact on health 
outcomes, including those associated with T2DM.8
As a potential guide for GPP wanting to improve their 
approach to diabetes care, we have shown previously 
through cross-sectional analysis for the year of NDA 
data 2016–2017,13 that moving levels of local service 
activities and prescribing of metformin and sulpho-
nylurea from the median to the 90th percentile level 
could be associated with more than 200 000 additional 
patients in TGC and more than 60 000 fewer in HGR. 
The associations between change in SGLT-2 inhibitor 
and DPP-4 inhibitor prescription at a practice level and 
the proportions at TGC and HGR may be important, if 
the link is causative.14
In terms of cost, improving glucose control by using 
newer drugs would increase costs. For example, we 
speculate that an investment of £50 million in addi-
tional SGLT-2 inhibitors in those practices prescribing 
around or below the national average to include an 
additional 100 000 patients might bring as many as 
12 500 out of the HGR group and 20 000 people into the 
TGC group. This additional acquisition cost could be 
offset by relative savings on longer term cost reduction 
from, for example, lower rates of comorbidity. While 
the quoted NNT figures are not definitive, based on 
this modelling they provide a framework within which 
Figure 3 Cross-sectional analysis of potential impact on patient numbers. BP, blood pressure; DPP-4, dipeptidyl 
peptidase-4 inhibitor; HGR, higher glycaemic risk; SGLT-2, sodium–glucose cotransporter-2 inhibitor; TGC, target glycaemic 
control. 
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changes in clinical prescribing can be more accurately 
defined.
We accept that the methodology applied is relatively 
new and that the findings concerning the relative effect 
of different diabetes treatments need to be replicated 
in other T2DM populations. Nevertheless, the authors 
believe these results make an important contribution to 
the debate about potential impact of different prescribing 
and service activity approaches on glycaemic control.
COnClusIOn
The methodology described here gives the opportunity 
for GPP to evaluate their effectiveness to manage T2DM 
in the light of three key categories of ‘medicines’, ‘service 
activities’ and ‘demographics’. The findings from this 
study emphasise the importance of practice level organ-
isation of testing/recall and of care processes, and the 
importance of proactively reviewing and ‘fine tuning’ 
their prescribing behaviour more in line with higher 
performing practices, with the goal of improved outcomes 
for their T2DM patients.
GPP using more legacy therapies such as sulpho-
nylurea/insulin attain poorer outcomes, while those 
applying holistic patient management and use of newer 
molecules are associated with improved outcomes. If all 
GPP adopted similar service activities and prescribing 
practices to those of the top decile for both TGC and 
HGR groups, outcomes could be substantially improved.
Figure 4 Reconciling actual change in numbers of TGC and HGR between 2015_16 and 2016_17 by applying the model 
regression coefficients s to the annual change in value of the selected factors and then multiplying the result by the national 
T2DM population, along with Numbers Needed to Treat (NNT). BP, blood pressure; DPP-4, dipeptidyl peptidase-4 inhibitor; 
GLP-1, glucagon-like peptide-1 agonist; HGR, higher glycaemic risk; SGLT-2, sodium–glucose cotransporter-2 inhibitor; TGC, 
target glycaemic control 
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Open access
Our findings demonstrate that the range of factors 
in the primary care management of T2DM, including 
monitoring and prescribing, can have significant positive 
and in some cases negative impact on patient outcomes, 
allowing for potential causal confounding factors. Under-
standing the specific relative contribution each factor 
makes to patient outcomes provides an important starting 
point for a more accurate prioritisation of clinical and 
funding activities, and therefore improved management 
of everyone with T2DM. Looking ahead, these findings 
can form the basis of an ‘associated best practice’ bench-
mark against which GPP could be evaluated and areas for 
improvement more easily identified.
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